Statement on the safe use of the nptII antibiotic resistance marker gene in genetically modified plants by the Scientific Panel on genetically modified organisms (GMO) by 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
General rights 
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners 
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. 
 
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research. 
• You may not further distribute the material or use it for any profit-making activity or commercial gain 
• You may freely distribute the URL identifying the publication in the public portal  
 
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately 
and investigate your claim. 
   
 
Downloaded from orbit.dtu.dk on: Dec 18, 2017
Statement on the safe use of the nptII antibiotic resistance marker gene in genetically
modified plants by the Scientific Panel on genetically modified organisms (GMO)
EFSA Publication; Sørensen, Ilona Kryspin
Publication date:
2007
Document Version
Publisher's PDF, also known as Version of record
Link back to DTU Orbit
Citation (APA):
EFSA Publication (2007). Statement on the safe use of the nptII antibiotic resistance marker gene in genetically
modified plants by the Scientific Panel on genetically modified organisms (GMO). European Food Safety
Authority.
  
 
 
 
 
http://www.efsa.europa.eu 
 
1 
 
Statement of the Scientific Panel on Genetically Modified Organisms  
on the safe use of the nptII antibiotic resistance marker gene  
in genetically modified plants 
 
adopted on 22-23 March 2007 
1. BACKGROUND 
 
The Commission is currently considering the authorisation for placing on the market of the genetically 
modified (GM) potato line EH92-527-1 under Regulation (EC) No 1829/2003 on GM food and feed and 
under Directive 2001/18/EC, part C. The GM potato, developed for amylopectin production, also contains a 
nptII gene used as a selectable marker. The nptII gene codes for an aminoglycoside phosphotransferase 
conferring resistance to antibiotics such as kanamycin, neomycin, paromomycin, butirosin, gentamycin B 
and geneticin. 
 
Directive 2001/18/EC (EC, 2001) states that Member States and the Commission shall ensure that GMOs 
which contain genes expressing resistance to antibiotics in use for medical or veterinary treatment are 
taken into particular consideration when carrying out an environmental risk assessment. This is with a view 
to identify and phase out antibiotic resistance marker genes (ARMGs) in GMOs which may have adverse 
effects on human health and the environment. 
 
Over the last years, the use of antibiotic resistance marker genes for selection of GM plants, and which have 
been subject of safety assessment under Part C of the Directive 2001/18/EC, has been limited to the nptII 
gene. Some applications of GM plants submitted under Regulation No 1829/2003 also include the use of 
the nptII gene as a selectable marker, while in other cases the nptII gene has been excised after selection, 
or other markers such as the epsps and pat genes coding for herbicide tolerance were used. No other 
antibiotic resistance marker genes are currently present in applications submitted for approval.  
 
According to an earlier conclusion of the Scientific Panel on Genetically Modified Organisms (GMO Panel) 
(EFSA, 2004)1 the use of nptII as a selectable marker in genetically modified plants and, more specifically, 
in the potato line EH92-527-1 (EFSA, 2006), does not pose a risk to the environment or to human and 
animal health. This conclusion was based on the low probability of gene transfer from plants to bacteria, the 
already widespread presence of the nptII gene in bacterial populations, and the limited use of kanamycin 
and neomycin in human and veterinary medicine.  
 
The Commission sought confirmation from the European Medicines Agency (EMEA) as to whether, 
notwithstanding a WHO working group classification of aminoglycosides as critically important 
antibacterials (WHO, 2005), the current or possible future uses of the antibiotics for which the nptII gene 
                                                     
1http://www.efsa.europa.eu/etc/medialib/efsa/science/gmo/gmo_opinions/384.Par.0001.File.dat/opinion_gmo_05_en1.pdf 
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confers resistance is still in line with the earlier EFSA opinion. The EMEA was asked to consider whether the 
current or possible future medicinal uses of these antibiotics might have an impact on the earlier 
conclusions of the GMO Panel. 
 
In response to the Commission’s request, the EMEA indicated that aminoglycosides comprise a class of 
antibiotics that has become increasingly important in the prevention and treatment of serious invasive 
bacterial infections in humans, since Gram-negative bacteria (and tuberculosis bacteria) are becoming 
resistant to other classes of antibiotics. The EMEA also stressed that, although kanamycin and neomycin are 
used relatively infrequently, the potential development of new chemical entities similar to kanamycin and 
neomycin should also be taken into account. In addition, although the veterinary use of kanamycin and 
neomycin is currently limited, aminoglycosides as a group are a class of antibiotics critically important for 
veterinary medicine.  
 
The EMEA considered that its competence did not extend to a detailed consideration of the likelihood of 
gene transfer of antibiotic resistance genes from plant material to bacteria of man and animals. 
 
Subsequently, the Commission requested EFSA (letter dated March 2, 2007) to consider the information 
provided by the EMEA and to indicate the potential consequences of the EMEA’s conclusions on the safety 
assessment of the nptII gene and, where applicable, on the specific assessments of GMOs and derived food 
and feed. 
 
2. ASSESSMENT 
A concern with respect to the presence of antibiotic resistance marker genes in GM plants is the potential 
for increased resistance to antibiotics in humans, animals and in organisms in the wider environment as a 
result of horizontal gene transfer. The safety assessment of the GMO Panel concerning the presence of the 
nptII gene in GM plants builds on a number of considerations. Key elements are the very low likelihood of 
transfer of a functional nptII gene (or any other gene), from GM plant material to microorganisms, and the 
prevalence of the nptII gene in bacterial clinical isolates and in the environment. 
2.1. Likelihood of transfer of the nptII gene from the genome of GM plants to bacteria 
In considering the probability of functional gene transfer from plants into bacteria in the environment or 
human/animal gut, several aspects need to be taken into account: 
(i) DNA is released from plant material by normal digestion processes that take place in the 
gastrointestinal tract, or by activities of nucleases present in various organisms in the environment. 
(ii) The probability that bacteria will be exposed to DNA stretches long enough to contain the intact nptII 
gene is very low because of the above mentioned digestion and degradation processes (Lorenz and 
Wackernagel, 1994). 
(iii) The nptII gene from plant material can only be taken up by competent bacteria via natural 
transformation, a process that occurs infrequently in many bacteria and in most environmental 
conditions (Davison, 1999). 
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(iv) If the intact nptII gene enters the bacteria, it will be rapidly degraded by restriction endonucleases in 
many bacterial cells which possess DNA restriction systems in order to destroy foreign DNA 
(Davison, 1999). 
(v) If the intact nptII gene does indeed survive, the probability of its incorporation into the bacterial 
genome is very low unless there are homologous regions already present in the bacterial genome. 
Gene transfer from plants to bacteria has only been demonstrated under laboratory conditions when 
regions of homology were already present in the recipient bacterium (Bennett et al., 2004, de Vries 
et al., 2001, de Vries and Wackernagel, 2002, Kay et al., 2002, Tepfer et al., 2003) . 
(vi) Expression of the incorporated nptII gene is unlikely considering that in GM plant material the nptII 
gene is under the control of a promoter with preferential expression in plants, which does not 
support its efficient expression in bacteria. 
(vii) Stable integration and inheritance of the nptII gene in the host bacterium is not likely in the absence 
of selective pressure from a relevant antibiotic. 
When all of the above mentioned aspects are taken into account, the probability of functional gene transfer 
from plants into microorganisms is extremely low. It is not surprising that transfer of an antibiotic resistance 
marker from GM plants to bacteria has not been observed under natural conditions (Gay and Gillespie, 
2005).  
 
The EMEA has indicated that under laboratory conditions gene transfer from plants to bacteria has been 
demonstrated. EFSA has addressed this issue more extensively in its Opinion of 2004 (section 4) (EFSA, 
2004). Gene transfer from plants to bacteria has only been demonstrated in a few highly transformable 
bacterial species (e.g., Acinetobacter sp. BD413 or Pseudomonas stutzeri) under artificial and forced 
laboratory conditions when regions of homology were already present in the recipient bacterium (Bennett et 
al., 2004, de Vries et al., 2001, de Vries and Wackernagel, 2002, Kay et al., 2002, Tepfer et al., 2003). In 
the absence of this optimisation of the process and selection pressure, resistance gene transfer from GM 
plants to bacteria, even in the laboratory, could not be demonstrated (Gebhard and Smalla, 1998). 
2.2. Prevalence of the nptII gene in soil, humans and animals 
As indicated in the Opinion (of the GMO Panel) on the use of antibiotic resistance genes as markers in GM 
plants, antibiotic resistance is a common feature in natural microbial communities in soils, aquatic systems, 
and habitats associated with animals and humans (EFSA, 2004).  
 
There is already a widespread presence of nptII in the soil environment as evidenced from DNA-based work 
with nptII as a probe in different locations in Western Europe (NSCFFS, 2005, Smalla et al., 1993) and in the 
USA (Leff et al., 1993).  
 
Studies indicate that, as expected of a gene located on a transposable genetic element, nptII is located on a 
wide range of replicons in bacterial clinical isolates from humans (Alvarez and Mendoza, 1992, Chang et al., 
1992, Flamm et al., 1993). The nptII gene was present in 2.5% of bacterial clinical isolates resistant to 
kanamycin and neomycin collected between 1987 and 1991 in several European and Central and South 
American countries (Shaw et al., 1993). Studies on the prevalence of the nptII gene in animal-associated 
bacterial populations have not been found in the scientific literature. 
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2.3. Contribution of the nptII gene to the prevalence of resistance to kanamycin 
Kanamycin-resistant bacteria are ubiquitous in nature. Selective plating of different environmental samples 
on kanamycin-containing medium reduced the microbial count from 107 to 104 CFU/g (Smalla and van 
Elsas, 1996, Smalla et al., 1993). Only a fraction of kanamycin-resistant bacteria contain the nptII (aph(3’)-
IIa) gene, the other resistant bacteria having different genes and/or other mechanisms conferring 
kanamycin resistance. The nptII gene has been reported to occur naturally only in eubacteria. In one survey, 
3 out of 184 kanamycin resistant bacterial isolates from three stream sites in the USA (Leff et al., 1993) 
and 44 out of 355 from different habitats in the Netherlands (Smalla et al., 1993) contained nptII 
sequences. 
2.4. Potential mutations of the nptII gene resulting in resistance to other antibiotics 
As reported in the opinion of the GMO Panel on antibiotic resistance genes as markers in GM plants (EFSA, 
2004), resistance towards amikacin, an important reserve antibiotic could be obtained under laboratory 
conditions and was the result of a mutated nptII gene and a diminished rate of amikacin uptake into the 
bacterial cell (Perlin and Lerner, 1986). The increased affinity of a mutated nptII gene product for amikacin 
was later confirmed by site-directed mutagenesis which resulted in one altered nucleotide in the gene and 
an eight-fold increase in amikacin resistance in E.coli (Kocabiyik and Perlin, 1992). It has been suggested 
that the increased affinity for amikacin conferred by this mutation, might impair the clinical effectiveness of 
the drug. However, to date no clinical amikacin resistant strains with a mutated nptII gene have been 
identified.  
3. CONCLUSIONS  
The GMO Panel agrees with the EMEA that the preservation of the therapeutic potential of the 
aminoglycoside group of antibiotics is important. The Panel is also of the opinion that the therapeutic effect 
of these antibiotics will not be compromised by the presence of the nptII gene in GM plants, given the 
extremely low probability of gene transfer from plants to bacteria and its subsequent expression. 
Furthermore, the GMO Panel considers it very unlikely that the presence of the nptII gene in GM plants will 
change the existing widespread prevalence of this antibiotic resistance gene in bacterial sources in the 
environment. The GMO Panel also points to evidence which indicates that integration of the nptII gene would 
only be one of many mechanisms by which bacteria could become resistant to aminoglycosides such as 
kanamycin.  
 
Therefore, the GMO Panel reiterates its earlier conclusions (EFSA, 2004) that the use of the nptII gene as 
selectable marker in GM plants (and derived food or feed) does not pose a risk to human or animal health or 
to the environment. The GMO Panel also confirms earlier safety assessments of GM plants and derived 
food/feed comprising the nptII gene.  
 
The GMO Panel emphasizes that the use of antibiotic resistance marker genes in GM plants has been the 
subject of several reviews (Gay and Gillespie, 2005, Goldstein et al., 2005, Miki and McHugh, 2004, Nap et 
al., 1992, Nielsen et al., 1998, Ramessar et al., 2007) and expert consultations: Working Party of the British 
Society for Antimicrobial Chemotherapy (Bennett et al., 2004), FAO/WHO Consultation on Foods Derived 
from Biotechnology (FAO/WHO, 2000), Scientific Steering Committee of the European Commission (SSC, 
1999) Zentrale Kommission für die Biologische Sicherheit, DE (ZKBS, 1999), The Advisory Committee on 
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Novel Foods and Processes, UK (ACNFP, 1996). It has been concluded in these reports that the frequencies 
of gene transfer from plants to bacteria are likely to be extremely low and that the presence of antibiotic 
resistance marker genes, and in particular the nptII gene, in GM plants do not pose a relevant risk to human 
or animal health or to the environment. 
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1. Letter from DG SANCO, dated 2 March 2007, concerning the presence of the nptII resistance gene in 
genetically modified organisms (ref. SANCO/E1/SG/cc (2007)D/510137).  
 
2. Document from the EMEA Committee for Medicinal Products for Veterinary Use and Committee for 
Medicinal Products for Human Use, dated 22 February 2007, entitled “Presence of the antibiotic resistance 
marker gene nptII in GM plants for food and feed uses”, (ref. EMEA/CVMP/56937/2007-Final). 
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